Alt5 Sigma Corporation (ALTS)

$5.95 -0.01 (-0.17%)
Market Cap 83.85M
Revenue (ttm) 0.00
Net Income (ttm) -7.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.38
Volume 109,700
Avg Vol 208,924
Day's Range N/A - N/A
Shares Out 14.07M
Stochastic %K 45%
Beta 1.86
Analysts Strong Buy
Price Target N/A

Latest News on ALTS

ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing

Jan 15, 2025, 7:00 AM EST - 3 days ago

ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing

Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week

Jan 10, 2025, 8:30 AM EST - 8 days ago

Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week

ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025

Jan 9, 2025, 11:30 AM EST - 9 days ago

ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025

ALT5 Sigma Announces Results of 2024 AGM and Corporate Update

Dec 18, 2024, 4:00 PM EST - 4 weeks ago

ALT5 Sigma Announces Results of 2024 AGM and Corporate Update

ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024

Nov 12, 2024, 5:23 PM EST - 2 months ago

ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024

ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors

Nov 6, 2024, 8:30 AM EST - 2 months ago

ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation Announces Participation at the Spartan Capital Investor Conference

Oct 30, 2024, 10:30 AM EDT - 2 months ago

ALT5 Sigma Corporation Announces Participation at the Spartan Capital Investor Conference

ALT5 Sigma to Exhibit at Money20/20 October 27-30, 2024

Oct 23, 2024, 5:00 PM EDT - 3 months ago

ALT5 Sigma to Exhibit at Money20/20 October 27-30, 2024

ALT5 Sigma Reports a Record Month at Over $240 Million in Transaction Volume

Oct 9, 2024, 8:30 AM EDT - 3 months ago

ALT5 Sigma Reports a Record Month at Over $240 Million in Transaction Volume

ALT5 Announces Plan to Separate Into Two Independent Publicly Traded Companies

Oct 2, 2024, 8:30 AM EDT - 3 months ago

ALT5 Announces Plan to Separate Into Two Independent Publicly Traded Companies

ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024

Sep 10, 2024, 11:00 AM EDT - 4 months ago

ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024

ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024

Sep 9, 2024, 8:00 AM EDT - 4 months ago

ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024

ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer

Aug 26, 2024, 8:45 AM EDT - 5 months ago

ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer

ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024

Aug 23, 2024, 11:00 AM EDT - 5 months ago

ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024

ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024

Aug 19, 2024, 6:30 PM EDT - 5 months ago

ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024

ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024

Aug 13, 2024, 8:30 AM EDT - 5 months ago

ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024

ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024

Jul 25, 2024, 8:30 AM EDT - 6 months ago

ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024

JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

Jul 12, 2024, 6:22 PM EDT - 6 months ago

JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

Jul 10, 2024, 8:30 AM EDT - 6 months ago

JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

Jun 26, 2024, 7:30 AM EDT - 7 months ago

JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORM

Jun 25, 2024, 7:30 AM EDT - 7 months ago

ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORM

JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024

Jun 13, 2024, 7:30 AM EDT - 7 months ago

JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024

ALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation Market

Jun 11, 2024, 8:30 AM EDT - 7 months ago

ALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation Market

JanOne Inc. added to the Russell Microcap® Index

Jun 3, 2024, 12:05 PM EDT - 8 months ago

JanOne Inc. added to the Russell Microcap® Index

ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshow

May 28, 2024, 2:00 AM EDT - 8 months ago

ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshow

JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain Fintech

May 16, 2024, 4:00 PM EDT - 8 months ago

JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain Fintech

JanOne Regains Compliance with Nasdaq's Listing Requirements

Mar 15, 2024, 9:00 AM EDT - 11 months ago

JanOne Regains Compliance with Nasdaq's Listing Requirements

JanOne to Present at the Dawson James 8th Annual Investment Conference

Sep 21, 2023, 11:30 AM EDT - 1 year ago

JanOne to Present at the Dawson James 8th Annual Investment Conference

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

Aug 31, 2023, 1:30 PM EDT - 1 year ago

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

Aug 29, 2023, 1:30 PM EDT - 1 year ago

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

Aug 25, 2023, 2:30 PM EDT - 1 year ago

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 22, 2023, 5:30 PM EDT - 1 year ago

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 18, 2023, 7:00 PM EDT - 1 year ago

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

Aug 18, 2023, 12:42 PM EDT - 1 year ago

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

Jun 28, 2023, 8:30 AM EDT - 1 year ago

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

JanOne Completes Pre-IND Meeting with FDA on Jan123

Apr 18, 2023, 8:30 AM EDT - 1 year ago

JanOne Completes Pre-IND Meeting with FDA on Jan123

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

Apr 13, 2023, 8:30 AM EDT - 1 year ago

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

Mar 24, 2023, 11:02 AM EDT - 1 year ago

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

Mar 23, 2023, 8:30 AM EDT - 1 year ago

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

Mar 23, 2023, 8:00 AM EDT - 1 year ago

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

Mar 22, 2023, 8:30 AM EDT - 1 year ago

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

Feb 22, 2023, 8:30 AM EST - 2 years ago

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

Jan 26, 2023, 8:30 AM EST - 2 years ago

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

Jan 10, 2023, 8:30 AM EST - 2 years ago

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

Sep 16, 2022, 9:30 AM EDT - 2 years ago

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website

Jul 5, 2022, 9:00 AM EDT - 2 years ago

ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website

JanOne Inc. Announces an Improved Formulation of JAN101

Jun 28, 2022, 9:00 AM EDT - 2 years ago

JanOne Inc. Announces an Improved Formulation of JAN101

ARCA Recycling, Inc., a Subsidiary of JanOne Inc., Opens Three New Recycling Centers in Washington, California and New Jersey

Jun 9, 2022, 8:30 AM EDT - 2 years ago

ARCA Recycling, Inc., a Subsidiary of JanOne Inc., Opens Three New Recycling Centers in Washington, California and New Jersey

Why JanOne Shares Are Skyrocketing Today

Jun 7, 2022, 10:38 AM EDT - 2 years ago

Why JanOne Shares Are Skyrocketing Today

JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101

Jun 7, 2022, 8:30 AM EDT - 2 years ago

JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101